Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Vyne Therapeutics’ SEC disclosures can feel like decoding lab notes—clinical trial amendments, BET inhibitor research costs, and equity raises are scattered across hundreds of pages. If you have ever asked, “Where do I find the details of Vyne Therapeutics’ latest Phase 2 update?” or hunted for Vyne Therapeutics insider trading Form 4 transactions, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate R&D jargon into plain English, flagging cash-runway metrics in the Vyne Therapeutics quarterly earnings report 10-Q filing and explaining risk factors in the Vyne Therapeutics annual report 10-K simplified. Real-time alerts push Vyne Therapeutics Form 4 insider transactions real-time to your dashboard, while “understanding Vyne Therapeutics SEC documents with AI” guides break down every Vyne Therapeutics 8-K material events explained—from trial readouts to licensing deals. Need board-level context? The Vyne Therapeutics proxy statement executive compensation section highlights stock options for scientific leadership, and our platform links each Vyne Therapeutics executive stock transactions Form 4 back to those incentives.
Comprehensive coverage means no document is missed—10-K, 10-Q, S-3, S-8, or 13D. Investors use our tools to (i) compare quarter-over-quarter R&D spend, (ii) monitor dilution risk ahead of capital raises, and (iii) spot management’s confidence via “Vyne Therapeutics earnings report filing analysis.” Whether you are a dermatologist tracking BD2-selective breakthroughs or an analyst modeling cash burn, Stock Titan delivers Vyne Therapeutics SEC filings explained simply, saving hours and sharpening decisions.
Eventide Asset Management, LLC and two affiliated individuals filed an amendment on Schedule 13G disclosing beneficial ownership of 1,849,597 shares of VYNE Therapeutics common stock, representing 9.99% of the class based on 16,664,892 shares outstanding. The filing states these holdings reflect common stock issuable upon exercise of pre-funded warrants exercisable for up to 5,287,413 shares, but exercise is limited so the holder will not exceed 9.99%. The amendment explains the change was to disclose a different mix of security types and includes signatures dated August 14, 2025.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,370,938 shares of VYNE Therapeutics, representing 8.23% of the outstanding common stock. The reported position reflects shared voting and shared dispositive power only; the reporting persons state they have no sole voting or sole dispositive power over these shares.
The holding is reported as held by the Cormorant Funds, and the filing notes that Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or sale proceeds for more than 5% of the shares. The percentage is calculated using 16,664,892 shares outstanding as reported by the issuer as of May 1, 2025. The reporting persons certify the shares are held in the ordinary course of business and not to influence control of the issuer.
VYNE Therapeutics furnished a press release reporting financial results for the quarter ended June 30, 2025; that press release is attached as Exhibit 99.1. The filing states the exhibit is being furnished and not "filed" for purposes of Section 18 of the Exchange Act. The report itself does not include the financial figures in this 8-K.
The registrant also disclosed that Christine Borowski, Ph.D. and Anthony Bruno resigned from the board effective immediately, each leaving their committee roles; the company stated the resignations were not due to any disagreement with the company or board and expressed thanks for their contributions.
FAQ
What is the current stock price of Vyne Therapeutics (VYNE)?
What is the market cap of Vyne Therapeutics (VYNE)?
